2010 Epilepsy Pipeline Update Conference Webcasts

Epilepsy.com Content
Wiki Content

Your Email: *

Your Name: *

Send To: *
Enter multiple addresses on separate lines or separate them with commas.

Message Subject: (Your Name) has forwarded a page to you from epilepsy.com

Message Body: (Your Name) thought you would enjoy the following page from epilepsy.com.

Captcha
Type the words in the image

Email this page
Share on Twitter
Share on Facebook
View/Print content

Read an overview of the conference at http://my.epilepsy.com/node/985708

Day 1, Thursday, February 25, 2010

Registration and Continental Breakfast

Welcome & Overview

Joyce Cramer, President, Epilepsy Therapy Project

Session Webcast

Keynote Lecture: How Open Innovation Advances Medical Breakthroughs: Business Models for 2010

Henry Chesbrough PhD, Center for Innovation, Haas Business School, UC Berkeley
He coined the term open innovation and is the author of Open Innovation: The New Imperative for Creating and Profiting from Technology (Harvard Business School Press, 2003),Open Business Models: How to Thrive in the New Innovation Landscape (HBS Press, 2006), and Open Innovation: Researching a New Paradigm (Oxford, 2006).

Session Webcast

The Science of Epilepsy: Detecting and Aborting Seizures

Robert Fisher MD, PhD, Stanford University
Discussion of technologies including external & intracranial stimulation, seizure detection algorithms, intracranial drug delivery, and hybrids.

Session Webcast View Abstract (32k PDF)

Pros and Cons: Will these new devices fill the gap between drug therapy and surgery?
Ivan Osorio MD (University of Kansas)

Session Webcast View Abstract (26k PDF)

Pipeline Review: Early Stage & Marketed Devices, Hybrids

What device will solve the seizure detection problem? This session will provide highlights of a series of novel emerging detection/stimulation devices and drug-device hybrids. Presenters will briefly answer a series of questions describing their concepts and plans, followed by questions from the audience.

Moderator: Frank Fischer (Neuropace)

"5 Slides in 5 Minutes"

How does the device/hybrid work?
What is the IP status?
What are the development challenges?
What are the timelines, milestones and financial needs?
What does it bring to the marketplace?

Part 1

Cyberonics, Vagus Nerve Stimulation Session Webcast View Abstract (38k PDF)	Milton Morris PhD
Medtronic, Stimulation of the Anterior Nucleus of Thalamus (SANTE) Session Webcast View Abstract (28k PDF)	Robert Fisher MD, PhD
NeuroPace, Responsive Neurostimulation System Session Webcast View Abstract (28k PDF)	Martha Morrell MD
NeuroVista, Seizure Advisory System Session Webcast View Abstract (27k PDF)	Doug Sheffield VMD, PhD
Visualase, MRI-Guided Laser Surgery Session Webcast View Abstract (166k PDF)	William Hoffman
Smart Monitor, SmartWatch Alert Session Webcast View Abstract (35k PDF)	Anoo Nathan PhD
BioLert, Watch Alert Session Webcast View Abstract (32k PDF)	Ruben Kuzniecky MD
University of Kansas, Brain Cooling Session Webcast View Abstract (27k PDF)	Ivan Osorio MD

Part 2: Continuation of Pipeline Review: Early Stage & Marketed Devices, Hybrids

New York University, subdural pharmacotherapy device Session Webcast View Abstract (30k PDF)	Ruben Kuzniecky MD
Advanced Neurometrics, Ambulatory EEG Cap Session Webcast View Abstract (25k PDF)	Eric Duff
Epinano, Magnetonanoparticles for MRI Session Webcast View Abstract (26k PDF)	Massoud Akhtari PhD
SynapCell, Predictive models of epilepsies in rodents Session Webcast View Abstract (24k PDF)	Corinne Roucard PhD
CanCog Technologies, Naturally Occurring Dog Models of Epilepsy Session Webcast View Abstract (26k PDF)	Howard Dobson
Texas Institute of Genomic Medicine, Drug Development Using a Mouse Gene-Trap Mutant Resource Session Webcast	Richard Finnell PhD
NeuroInDx (UCLA), Peripheral Blood Transcriptome Biomarkers for the Identification of Preepileptic Patients. Session Webcast View Abstract (27k PDF)	Stanislav L. Karsten PhD

The Science of Epilepsy: Mechanisms of Action of Drugs and Biologics

Mechanisms of Action of Drugs and Biologics
Michael Rogawski MD, PhD, University of California, Davis

Presentation Not Available

Pros and Cons: Do Mechanisms of Action Matter?
Roger Porter MD (Formerly Wyeth & NINDA, Consultant)

Session Webcast

Screening models: Now and future efficiencies in drug development

Predictive for efficacy and tolerability, and mechanism of action

H. Steven White PhD, University of Utah

Session Webcast View Abstract (27k PDF)

Pros and Cons: Do we need new models? How do we test novel approaches (e.g., anti-inflammatory)?
Stephen Collins MD, PhD (Neurotherapeutics)

Session Webcast

Pipeline Review: Early Stage Drugs, Biologics

Where will the next epilepsy blockbuster come from? This session will provide highlights of a series of novel emerging drugs & biologics. Presenters will briefly answer a series of questions describing their concepts and plans, followed by questions from the audience.

Moderator: Dan O’Connell (NeuroVentures)

"5 Slides in 5 Minutes"

How does the drug/biologic work?
What is the IP status?
What are the development challenges?
What are the timelines, milestones and financial needs?
What does it bring to the marketplace?

Neurologix, NPY Gene Transfer Session Webcast	Matthew During MD, PhD
Neuroadjuvants, Galanin NTX 5055 Session Webcast View Abstract (28k PDF)	H. Steven White, PhD
Asklepios, Galanin gene transfer Session Webcast View Abstract (26k PDF)	Scott McPhee PhD, MPH
MediPro Pharma, MPP-021 Session Webcast View Abstract (32k PDF)	Irina Shcherbakova PhD
NeuroTherapeutics, NTP-2014 Session Webcast View Abstract (31k PDF)	Stephen Collins MD, PhD
Catalyst, Vigabatrin Analog Session Webcast View Abstract (27k PDF)	Charles Gorodetzky MD, PhD
Medkura Inc., Pulmonary Propofol Presentation Not Available MedGenesis, Convection enhanced toxin delivery Presentation Not Available	Michael Rogawski MD, PhD
Legacy Research, Adenosine Releasing Implants Session Webcast View Abstract (44k PDF)	Detlev Boison PhD
Paloma Pharmaceuticals, P529 Dual TORC1/2 Akt/mTOR inhibitor Session Webcast View Abstract (30k PDF)	David Sherris PhD
BioLink, Dynamin Inhibitors Session Webcast View Abstract (28k PDF)	in absentia
Marinus, Ganaxolone neurosteroid Session Webcast View Abstract ( 26k PDF)	Gail Farfel MD
Supernus, Extended-release oxcarbazepine & topiramate Session Webcast View Abstract (26k PDF)	Paolo Baroldi MD
NeuroGenomeX, 2DG Neural Plasticity Session Webcast View Abstract (27k PDF)	Thomas Sutula MD, PhD
SK Life Science, New molecular entity Session Webcast View Abstract (23k PDF)	S. James Lee PhD

Panel: The Impact of Changes in Financing: How to Get Started & Keeping Going

What is the new Venture Capital Model?
Moderator: Heath Lukatch PhD (Novo Ventures)
Panelists: Thomas Beck MD (Fidelity Biosciences), Manuel Lopez-Figueroa PhD (Bay City Capital), Anand Mehra MD (Sofinnova), Roger Quy PhD (Technology Partners)

Session Webcast View Panel Topic (15k PDF)

Panel: Market Dynamics: The Value Proposition in Epilepsy and Beyond (Drugs & Devices)

Moderator: Nancy Santilli (Endo)
Panelists: Charles Cho MD (Palo Alto Investors), Stephen Collins MD, PhD (Neurotherapeutics), Sherrie Perkins (Cyberonics), Suzanne Giordano PhD (Pfizer), Matthew Simonian (UCB)

Presentation Not Available

Business Model for Partnering With a NonProfit Organization: Non-Dilutive Funding & Match-Making

Joyce Cramer, President, Epilepsy Therapy Project

Session Webcast

Networking Reception and Dinner

Day 2: Friday, February 26, 2010

The Science of Epilepsy: New Approaches

Orphan Indications and Novel Formulations

Overview of technology and formulation choices among extended release, intranasal, intra-muscular formulations, and special populations.
C. James Cloyd PhD, University of Minnesota

Session Webcast View Abstract (26k PDF)

Pros and Cons: Do Orphan Indications and Novel Formulations move us forward?
Jacqueline French MD (New York University)

Session Webcast

Pipeline Review: Phase 3 and Marketed Drugs

How useful is an indication for special populations? What strategies are useful for product life-extensions? What makes an epilepsy blockbuster? This session will provide highlights of a series of devices and drugs in late-stages of development and post-marketing. Presenters will briefly answer a series of questions describing their strategic planning, followed by questions from the audience.

Moderator: Jacqueline French MD (New York University)

"5 Slides in 5 Minutes"

How does the drug/device work?
What are its efficacy and tolerability characteristics?
What is the differentiation from other epilepsy treatments?
What additional indications are being evaluated or considered?
What are the challenges in product life-extension (value-added for payors after patent expiration)?

Sepracor, eslicarbazepine Session Webcast View Abstract (36k PDF)	Mark Versavel MD
Valeant/GSK, retigabine Session Webcast View Abstract (28k PDF)	Roger Porter MD
UCB, brivaracetam Session Webcast	Peter Verdru MD
OrthoMcNeil, carisbamate Session Webcast	Gerald Novak MD
King, IM diazepam Session Webcast View Abstract (29k PDF)	Veeraindar Goli MD,MBA,DFAPA
Eisai, perampanel Session Webcast	Francesco Bibbiani, MD
Lundbeck, Clobazam Session Webcast View Abstract (36k PDF)	Steven Sagar, MD
Eisai, Zonegran Session Webcast	Rav Seeruthun, MD
Eisai, Banzel Session Webcast	Francesco Bibbiani MD
UCB, Vimpat Session Webcast	Peter Verdru MD
Pfizer, Lyrica Presentation Not Available	Suzanne Giordano PhD
Lundbeck, Sabril Session Webcast View Abstract (30k PDF)	Steven Sagar MD
Clinical Trial Recruitment Session Webcast	Jacqueline French MD (New York University)

Planning for Reimbursement CMS, Part D, PBMs and other formulary access

Drugs: Rich Denness (UCB Pharma)

Presentation Not Available

Devices: Elizabeth Spurgin, B&D Consulting

Session Webcast

Panel: Reimbursement and Regulatory Issues

Novel & Modified Drugs, Stimulators & Drug Delivery systems

Moderator: Cynthia Rask MD (formerly FDA, Consultant)
Panelists: Rich Denness (Director, Managed Care Director, UCB), Elizabeth Spurgin (B&D Consulting)

Presentation Not Available

The Science of Epilepsy: Bio-Markers

Proteomics and Biomarkers: David Agus, MD (University of Southern California)

Presentation Not Available

Marker for Sudden Unexplained Death in Epilepsy [SUDEP]: Jeffrey Noebels MD, PhD (Baylor University)

Session Webcast

Common neuronal and extra-neuronal modulators of ion channels and a potential role in SUDEP: Geoffrey Pitt MD, PhD (Duke University)

Session Webcast

Panel: The Search For Markers for Localization-related (Partial Onset) Epilepsy

Genetics, Genomics, Genotypes, Phenotypes, Gene-By-Environment Interactions

Moderator: Dan Lowenstein MD, PhD (UCSF)

Panelists: David Agus (USC), Anatol Bragin PhD (NeuroIndx), Richard Finnell PhD (Texas Institute for Genomic Medicine), Jeffrey Noebels MD, PhD (Baylor), Geoffrey Pitt MD, PhD (Duke)

Session Webcast View Panel Topic (39k PDF)

Adjourn

Welcome to the Wiki. This space is created for epilepsy.com members to share their own experiences and expertise to help refine and expand the discussion around important topics.

No members have yet contributed to this topic. If you are not yet an epilepsy.com member, register today to get started on this Wiki topic and the many other advantages of being a member. If you are a member and wish to be the first to edit this Wiki topic, please make sure to login, then click on the orange "Start Wiki" button at the top of this page. Or, learn more about Wikis.

Member Login